When should a valproic acid (Depakote ER) level be drawn for a patient taking 1000 mg at bedtime?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Timing of Depakote ER Level Draw

For a patient taking 1000 mg Depakote ER at bedtime, the valproate level should be drawn as a trough level just before the next evening dose (approximately 24 hours after the last dose), or alternatively, a morning draw between 8-11 AM is acceptable but will read 18-25% higher than the true trough value. 1, 2

Optimal Timing Based on Pharmacokinetics

True Trough Sampling (Preferred)

  • Draw 21-24 hours after the evening dose (just before the next bedtime dose) to obtain the most accurate trough concentration 2
  • This timing provides concentration values within 3% of the true trough level 2
  • The therapeutic range for valproic acid is 50-100 mcg/mL, and accurate trough levels are essential for proper interpretation 1

Practical Morning Sampling (Acceptable Alternative)

  • If drawing 12-15 hours after an 8 PM dose (8-11 AM blood draw), expect plasma VPA concentrations to be 18-25% higher than the true trough value 2
  • If drawing 18-21 hours after the evening dose (2-5 PM blood draw), concentrations will be only 3-13% higher than trough, which may provide acceptable monitoring information 2
  • When dosed in the evening, maximum levels occur between midnight and 2 AM, with minimum levels between 10 PM and midnight 3

Critical Timing to Avoid

  • Avoid sampling 3-15 hours post-dose (peak period), as this represents the greatest deviation from trough and should only be done if there is a specific clinical need to assess peak concentrations 2
  • Despite the extended-release formulation creating a smooth concentration-time profile, timing does matter significantly for proper interpretation 2

Clinical Context for Level Monitoring

  • Levels should be checked if satisfactory clinical response has not been achieved to confirm concentrations are in the therapeutic range of 50-100 mcg/mL 1
  • Monitor for dose-related adverse effects, particularly thrombocytopenia, which increases significantly at concentrations ≥110 mcg/mL (females) or ≥135 mcg/mL (males) 1
  • Liver function tests should be performed prior to therapy and at frequent intervals, especially during the first six months 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.